Seminars in Oncology
Volume 37, Issue 1 , Pages 39-46 , February 2010

Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators

  • Aditya Bardia

      Affiliations

    • Department of Oncology, Johns Hopkins University, Baltimore, MD
    • ,
  • Charles Loprinzi

      Affiliations

    • Department of Oncology, Mayo Clinic, Rochester, MN
    • Corresponding Author InformationAddress correspondence to Charles Loprinzi, MD, Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905
    • ,
  • Axel Grothey

      Affiliations

    • Department of Oncology, Mayo Clinic, Rochester, MN
    • ,
  • Garth Nelson

      Affiliations

    • Department of Biostatistics, Mayo Clinic, Rochester, MN
    • ,
  • Steven Alberts

      Affiliations

    • Department of Oncology, Mayo Clinic, Rochester, MN
    • ,
  • Smitha Menon

      Affiliations

    • Department of Oncology, Mayo Clinic, Rochester, MN
    • ,
  • Stephan Thome

      Affiliations

    • Department of Preventive Medicine, Creighton University, Omaha, NE
    • ,
  • Sharlene Gill

      Affiliations

    • University of British Columbia, Vancouver, BC, Canada
    • ,
  • Dan Sargent

      Affiliations

    • Department of Biostatistics, Mayo Clinic, Rochester, MN

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. CA Cancer statistics, 2008. Cancer J Clin. 2008;58:71–96
  2. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators). N Engl J Med. 2004;350:2343–2351
  3. de Gramont A, Tournigand C, André T, Larsen AK, Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol. 2007;34(Suppl 1):S37–S40
  4. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008;CD005390
  5. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–991
  6. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol. 2000;19:972–979
  7. Loprinzi CL, Ravdin PM. Decision-making for patients with early breast cancer: individualized decisions for and by patients and their physicians. JNCCN. 2003;1:189–196
  8. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?. J Clin Oncol. 2004;22:1797–1806
  9. Loprinzi CL, Ravdin PM, De Laurentiis M, Novotny P. Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer?. J Clin Oncol. 1994;12:1422–1426
  10. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon (Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer). N Engl J Med. 1985;312:1604–1608
  11. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;23:2716–2725

 This work was supported by the following United States National Institutes of Health Grant-CA 124477 (PI Charles Loprinzi, MD).

PII: S0093-7754(09)00230-9

doi: 10.1053/j.seminoncol.2009.12.005

Seminars in Oncology
Volume 37, Issue 1 , Pages 39-46 , February 2010

Article Tools

* Image Usage & Resolution